` CERS (Cerus Corp) vs S&P 500 Comparison - Alpha Spread

CERS
vs
S&P 500

Over the past 12 months, CERS has underperformed S&P 500, delivering a return of -19% compared to the S&P 500's 24% growth.

Stocks Performance
CERS vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CERS vs S&P 500

Loading
CERS
S&P 500
Difference

Performance By Year
CERS vs S&P 500

Loading
CERS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cerus Corp vs Peers

S&P 500
CERS
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cerus Corp
Glance View

Market Cap
302.6m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
1.41 USD
Overvaluation 14%
Intrinsic Value
Price
Back to Top